Skip to main content
. 2019 Dec 3;14(12):e0225129. doi: 10.1371/journal.pone.0225129

Fig 4. The octanoylcarnitine level was significantly higher in estrogen receptor (ER)- and progesterone receptor (PR)-expressing tumors, but no significant difference was observed according to HER-2 expression.

Fig 4